Vascular Biogenics (NASDAQ:VBLT) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03), Fidelity Earnings reports. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.18 million. Vascular Biogenics had a negative net margin of 3,462.10% and a negative return on equity of 42.85%.
Shares of VBLT opened at $1.10 on Friday. Vascular Biogenics has a twelve month low of $0.90 and a twelve month high of $1.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.49 and a quick ratio of 5.49. The company’s fifty day simple moving average is $1.36 and its 200-day simple moving average is $1.29.
A number of equities research analysts recently issued reports on the stock. ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. Chardan Capital reaffirmed a “buy” rating and set a $3.25 price target on shares of Vascular Biogenics in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Vascular Biogenics in a research note on Friday. Zacks Investment Research downgraded shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research note on Thursday, January 2nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Vascular Biogenics has a consensus rating of “Buy” and an average target price of $2.50.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Story: What are Institutional Investors?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.